VANI Stock Analysis: Buy, Sell, or Hold?
VANI - Vivani Medical, Inc. Common Stock (DE)
$1.39
0.01 (0.36%)
â˛
5d:
-4.48%
30d:
+6.54%
90d:
+11.69%
WAIT
LOW Confidence
Analysis Updated: Aug 25, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When VANI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: VANI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: VANI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: VANI is currently trading at $1.39, which is considered fair relative to its 30-day fair value range of $1.31 to $1.41.
Technical Outlook: Technically, VANI is in a uptrend. Immediate support is located at $1.30, while resistance sits at $1.53.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (24th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.83 (+177.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VANI is in a uptrend. Immediate support is located at $1.30, while resistance sits at $1.53.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (24th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.83 (+177.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.31 -
$1.41
Company Quality Score
51/100
(HOLD)
Options IV Signal
24th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 24th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 177.8% below Wall St target ($3.83)
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.31 -
$1.41
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$0.19
(13.5%)
Support & Resistance Levels
Support Level
$1.30
Resistance Level
$1.53
Current Trend
Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.51
Wall Street Target
$3.83
(+177.8%)
Share & Embed Analysis
Last updated: August 25, 2026 1:56 PM ET
Data refreshes hourly during market hours. Next update: 2:56 PM
Data refreshes hourly during market hours. Next update: 2:56 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VANI showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Gregg Williams
BUY
1587301 shares
2026-04-15
Gregg Williams
BUY
1575231 shares
2026-03-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 41 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 48 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 60 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 33 SELL |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
